Concepedia

Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine

Kazuo Hattori, Yasunori Kohchi, Nobuhiro Oikawa, Hitomi Suda, Masako Ura, Tohru Ishikawa, Masanori Miwa, Mika Endoh, Hiroyuki Eda, Hiromi Tanimura,

Bioorganic & Medicinal Chemistry Letters · 2003 · 26 citations · 18 references

DOIFull text

Open access

Concepts

References

18

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

Masanori Miwa, Masako Ura, M Nishida et al. · European Journal of Cancer · 1998 · 1.2K citations

, , +12

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

Tetsuhiko Shirasaka, Yuji Shimamato, Hideyuki Ohshimo et al. · Anti-Cancer Drugs · 1996 · 824 citations

, , +16

Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.

Noriaki Sawada, T Ishikawa, Yu Fukase et al. · PubMed · 1998 · 425 citations

, , +13

Tumor Selective Delivery of 5-Fluorouracil by Capecitabine, a New Oral Fluoropyrimidine Carbamate, in Human Cancer Xenografts

Tohru Ishikawa, Masahiro Utoh, Noriaki Sawada et al. · Biochemical Pharmacology · 1998 · 330 citations

, , +16

Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.

Tohru Ishikawa, Fumiko Sekiguchi, Yu Fukase et al. · PubMed · 1998 · 304 citations

, , +16